Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Clin Cancer Res. 2016 May 6;22(19):4786–4796. doi: 10.1158/1078-0432.CCR-16-0048

Figure 4. Effect of RO4929097 treatment on proliferation, viability and CD133+ glioma stem cells in glioblastoma explants.

Figure 4

A, Immunofluorescent staining of Ki-67 in organotypic explants before and after treatment with RO. B, Quantification of Ki-67+ nuclei in patient explants before and after drug treatment (n=4). C, Cell viability in tumor explants treated with RO4929097, RT and TMZ, and the triple combination, as measured by CellTiter Glo Luminescent Assay (n=5). D, FACS-Analysis of cd133+ cells in tumor explants after drug treatment (n=5). (Ctrl = control, RO = RO4929097, RT = radiotherapy, TMZ = temozolomide; *p<0.05).